Financials
Financial year 2025
Worth noting
- The team shrank two years in a row.
Revenue
€ 14.6 million
▲ 17% vs 2024
Profit
Growing€ 2.6 million
▲ 2759% vs 2024
Debts
High€ 8.1 million
▲ 298% vs 2024
Ceres Pharmaceuticals from Gent, company number BE0407326754, closed financial year 2025 with a result of € 2.6 million after tax. For that financial year Ceres Pharmaceuticals recorded revenue of € 14.6 million and equity of € 1.3 million. Compared with financial year 2024, the result moved from € -99,159 to € 2.6 million. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
What happened at Ceres Pharmaceuticals?
What happened at Ceres Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.6 million. Source: NBB ↗
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 644,824 profit in 2021 to € 2.6 million profit in 2025.
Paid € 1.4 million in corporate taxes since 2021.
Best year ever: 2025, with € 2.6 million profit.
Paid out € 4 million in dividends to the owners in total.
A new publication or filing at Ceres Pharmaceuticals? We notify you, reason included.
Follow Ceres PharmaceuticalsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Anja Imschoot
Also active at: VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma +6 more
since 2024 · until 2030
Director · represented by Mario Debel
Also active at: VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma +5 more
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
Ceres Pharma
€ 35.3 million revenue · 2025
+15 more
Details
- Company number
- 0407.326.754
- VAT number
- BE 0407.326.754
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- Ceres Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 September 1970
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Detailhandel in drogisterijartikelen en onderhoudsproducten
Gespecialiseerde detailhandel in drogisterijartikelen en onderhoudsproducten
Detailhandel in drogisterijartikelen en onderhoudsproducten in gespecialiseerde winkels